Dogwood Therapeutics Inc (NASDAQ: DWTX)’s stock price has soared by 7.47 in relation to previous closing price of 4.82. Nevertheless, the company has seen a gain of 6.04% in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a corporate overview at the Sidoti Small-Cap Virtual Conference being held on Wednesday, June 11, 2025 – Thursday, June 12, 2025.
Is It Worth Investing in Dogwood Therapeutics Inc (NASDAQ: DWTX) Right Now?
The 36-month beta value for DWTX is at 1.89. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DWTX is 1.62M, and currently, shorts hold a 4.50% of that float. The average trading volume for DWTX on June 13, 2025 was 993.11K shares.
DWTX’s Market Performance
The stock of Dogwood Therapeutics Inc (DWTX) has seen a 6.04% increase in the past week, with a 6.80% rise in the past month, and a -32.99% fall in the past quarter. The volatility ratio for the week is 4.06%, and the volatility levels for the past 30 days are at 5.37% for DWTX. The simple moving average for the past 20 days is -1.77% for DWTX’s stock, with a 5.34% simple moving average for the past 200 days.
DWTX Trading at 6.88% from the 50-Day Moving Average
After a stumble in the market that brought DWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.31% of loss for the given period.
Stock Fundamentals for DWTX
The total capital return value is set at -0.16. Equity return is now at value -451.34, with -43.87 for asset returns.
Based on Dogwood Therapeutics Inc (DWTX), the company’s capital structure generated 0.91 points at debt to capital in total, while cash flow to debt ratio is standing at -0.17. The debt to equity ratio resting at 10.7. The interest coverage ratio of the stock is -50.72.
Currently, EBITDA for the company is -12.25 million with net debt to EBITDA at -2.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.43.
Conclusion
In conclusion, Dogwood Therapeutics Inc (DWTX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
